Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Consensus Price Target of $37.33

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $37.33.

Several research analysts recently issued reports on the company. Lucid Cap Mkts raised Eloxx Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 20th. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Zacks Research upgraded shares of Eloxx Pharmaceuticals to a “hold” rating in a report on Friday, October 16th. Lifesci Capital initiated coverage on Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Leerink Partners set a $32.00 price objective on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, September 18th.

Eloxx Pharmaceuticals Stock Down 2.8%

ELOX stock opened at $12.44 on Friday. The company has a 50 day moving average of $14.72 and a two-hundred day moving average of $13.71. Eloxx Pharmaceuticals has a 12-month low of $8.20 and a 12-month high of $23.40. The company has a market cap of $50.21 million, a price-to-earnings ratio of -8.08 and a beta of -1,918.69.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter. On average, research analysts anticipate that Eloxx Pharmaceuticals will post -2.61 EPS for the current year.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation therapy, an approach intended to encourage cells to read through certain genetic mutations and restore production of functional proteins.

The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote readthrough of nonsense mutations while seeking to limit the toxicity associated with older aminoglycoside compounds.